Primary splenic or hepatic
angiosarcomas are ultra-rare and aggressive
malignancies associated with poor prognosis. The mainstay treatments are surgical resection and
chemotherapy. We report a case of
angiosarcoma in a 50-year-old woman who presented with bruising,
fatigue,
ecchymosis, and hepatosplenomegaly. She was treated with the multi-
kinase inhibitor
sunitinib for 4 weeks before developing a splenic
hemorrhage and succumbing. Recent studies have demonstrated the clinical benefit of
immunotherapies in
angiosarcomas. Additionally, sequencing techniques have showcased the diverse molecular aberrations involved in
angiosarcomas, which offer opportunities for precision-matched targeted
therapies such as inhibitors of the
VEGF/VEGFR axis and PI3K/Akt/mTor pathway.